Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD By Ogkologos - November 7, 2025 228 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATHENA-MONO/GOG-3020/ENGOT-ov45 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR When Ovarian Cancer Returns, Surgery May Be a Good Choice for... January 12, 2022 Cancer in My Community: Addressing Regional Cancer Disparities in Peru August 24, 2023 Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian... April 21, 2026 Autumn and Letting Go September 29, 2021 Load more HOT NEWS Discovery of Tumor Suppressor Suggests New Cancer Treatment Strategies Delivering Palliative Care by Telehealth Meets the Needs of People with... Shannen Doherty Reveals She Has Stage IV Breast Cancer ELCC 2015 News: ‘Real-World’ EGFR Mutation Frequency Results From a Large...
